Share ownership Protagonist Therapeutics, Inc.

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-08 EST			5-day change	1st Jan Change
90.25 ^USD	+0.67%		+5.38%	+133.81%

12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI
11-06	Protagonist Therapeutics Q3 net loss widens to $39.3 mln	RE

Share class: Protagonist Therapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	59,598,018	56,800,672 ( 95.31 %)	0	95.31 %

Major shareholders: Protagonist Therapeutics, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 14.22 %	8,887,616	14.22 %	800 M $
Farallon Capital Management LLC 9.911 %	6,196,006	9.911 %	558 M $
RTW Investments LP 9.208 %	5,756,277	9.208 %	518 M $
Vanguard Fiduciary Trust Co. 6.81 %	4,257,229	6.81 %	383 M $
STATE STREET CORPORATION 5.064 %	3,165,795	5.064 %	285 M $
BVF, Inc. 4.096 %	2,560,916	4.096 %	230 M $
Johnson & Johnson Innovation - JJDC, Inc. 3.918 %	2,449,183	3.918 %	220 M $
Wellington Trust Co., NA 3.053 %	1,908,446	3.053 %	172 M $
UBS Financial Services, Inc. 3.027 %	1,892,308	3.027 %	170 M $
Deep Track Capital LP 2.744 %	1,715,691	2.744 %	154 M $
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	97.06%
Other	11.71%
State Street Corp.	5.06%
Individuals	1.69%
Manulife Financial Corp.	0.22%
Schweizerische Nationalbank	0.15%
Skandinaviska Enskilda Banken AB	0.13%
SEI Investments Co.	0.1%
Silvercrest Asset Management Group, Inc.	0.09%
Governments	0.04%
Baader Bank AG	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	100.67%
United Kingdom	7.2%
Individuals	1.69%
Switzerland	1.54%
Puerto Rico	1.12%
Canada	0.94%
Germany	0.89%
France	0.76%
Australia	0.67%
Hong Kong	0.27%
Sweden	0.16%
Ireland	0.12%
Luxembourg	0.11%
China	0.04%
Austria	0.02%
Spain	0.02%
Norway	0.02%
Japan	0.01%
Cayman Islands	0.01%

Based on 1000 largest holdings

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (Î±4Î²7) specific integrin antagonist for inflammatory bowel disease (IBD).

Employees

128

Sector

Biotechnology & Medical Research

Calendar

2025-12-08 - American Society of Hematology Meeting - Publication No: 5588

More about the company